Comparative study of safety and efficacy due to the dose change from 4 mg to 8 mg silodosin for benign prostatic hyperplasia with lower urinary tract symptoms.
Phase of Trial: Phase III
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Silodosin (Primary)
- Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
- Focus Pharmacodynamics; Therapeutic Use
- 25 Jul 2018 Status changed from recruiting to completed.
- 04 Sep 2012 New trial record